• Explore /
  • Poster
  • / Final overall survival (OS) analysis of PHEREXA: A randomized phase III trial of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy.

Final overall survival (OS) analysis of PHEREXA: A randomized phase III trial of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy.

Abstract Poster

Authors

null

Ander Urruticoechea

Onkologikoa Foundation, San Sebastían and Catalan Institute of Oncology-IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain

Ander Urruticoechea , Mohammed Rizwanullah , Seock-Ah Im , Antonio Carlos Sánchez Ruiz , Istvan Lang , Gianluca Tomasello , Hannah Douthwaite , Tanja Badovinac Crnjevic , Sarah Heeson , Jennifer Eng-Wong , Montserrat Munoz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

HER2-Positive

Clinical Trial Registration Number

NCT01026142

Citation

J Clin Oncol 36, 2018 (suppl; abstr 1013)

DOI

10.1200/JCO.2018.36.15_suppl.1013

Abstract #

1013

Poster Bd #

94

Abstract Disclosures

Similar Posters

First Author: Ander Urruticoechea

First Author: Bei Hu

First Author: Hideaki Bando

First Author: Daisuke Takahari